- Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
- Neurocrine Biosciences Reports First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
- Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
- Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
- Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
- Neurocrine Biosciences to Participate at Investor Conferences in March
More ▼
Key statistics
On Friday, Neurocrine Biosciences Inc (NBIX:NSQ) closed at 140.71, -5.16% below its 52-week high of 148.37, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 140.90 |
---|---|
High | 141.88 |
Low | 139.23 |
Bid | 130.00 |
Offer | 150.00 |
Previous close | 139.83 |
Average volume | 931.34k |
---|---|
Shares outstanding | 100.58m |
Free float | 99.31m |
P/E (TTM) | 38.67 |
Market cap | 14.15bn USD |
EPS (TTM) | 3.64 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼